Pediapharm

Medexus Pharmaceuticals recorded a net revenue decrease in the third quarter of 2026 from $30.0 million to $25.3 million, mainly due to intensified competition for Rupall. At the same time, gross margin improved to 53.6% and operating cash flow rose to $7.8 million, while cash on hand fell to $15.0 million. The company expects GRAFAPEX to generate positive cash flow by Q4 2026 and aims to secure increased reimbursement commitments over the next 12–18 months. » More on de.investing.com

Medexus Pharmaceuticals reported Q2 net revenue of USD 24.7m (prior year USD 26.3m) with an improved gross margin of 55.7% (prior year 53.7%). Graphopex contributed USD 6.2m in six months, manufacturing costs for Ixinity were cut by 30%, and net debt was reduced to USD 11.7m. Adjusted EBITDA was USD 4.4m, net loss amounted to USD 0.3m, and cash fell to USD 9.4m. For Q3 the company expects Graphopex revenues of USD 2.5–3.5m and anticipates a positive cash-flow contribution by Q4 2025. » More on de.investing.com

Medexus Pharmaceuticals saw its revenue fall to $24.8 million in the fourth quarter of 2025, but achieved record EBITDA of $20.2 million and a record net profit for the full year. The launch of the new product Grafifex showed strong early performance, and the company expects Grafifex to generate positive cash flow by the end of 2026. The stock rose 2.13% following the earnings announcement. » More on de.investing.com